Campbell & CO Investment Adviser LLC Boosts Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Campbell & CO Investment Adviser LLC increased its position in Pacira BioSciences, Inc. (NASDAQ:PCRXFree Report) by 217.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 25,431 shares of the company’s stock after purchasing an additional 17,432 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Pacira BioSciences were worth $858,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cape Investment Advisory Inc. purchased a new stake in Pacira BioSciences in the fourth quarter worth $97,000. Quest Partners LLC purchased a new stake in Pacira BioSciences in the fourth quarter worth $125,000. Global Alpha Capital Management Ltd. purchased a new stake in Pacira BioSciences in the fourth quarter worth $2,446,000. Hillsdale Investment Management Inc. purchased a new stake in Pacira BioSciences in the fourth quarter worth $4,521,000. Finally, PNC Financial Services Group Inc. grew its stake in Pacira BioSciences by 33.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,485 shares of the company’s stock worth $320,000 after purchasing an additional 2,387 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Trading Down 3.4 %

Shares of NASDAQ:PCRX opened at $29.12 on Friday. The company has a market cap of $1.36 billion, a P/E ratio of 20.36 and a beta of 0.87. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.81 and a quick ratio of 4.78. Pacira BioSciences, Inc. has a 1 year low of $25.33 and a 1 year high of $41.65. The stock’s fifty day moving average price is $28.53 and its 200-day moving average price is $29.75.

Pacira BioSciences (NASDAQ:PCRXGet Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The business had revenue of $167.12 million for the quarter, compared to the consensus estimate of $165.43 million. Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. Sell-side analysts expect that Pacira BioSciences, Inc. will post 2.13 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PCRX shares. Needham & Company LLC reduced their price target on Pacira BioSciences from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. JPMorgan Chase & Co. assumed coverage on Pacira BioSciences in a research note on Thursday, March 7th. They issued an “overweight” rating and a $45.00 target price on the stock. Royal Bank of Canada cut their target price on Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. Barclays cut their target price on Pacira BioSciences from $40.00 to $38.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $57.00 target price on shares of Pacira BioSciences in a research note on Wednesday, May 8th. Eleven analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $47.40.

Get Our Latest Research Report on PCRX

Pacira BioSciences Company Profile

(Free Report)

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.

See Also

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRXFree Report).

Institutional Ownership by Quarter for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.